Skip to main content

Table 3 Demographic characteristics and mean weight and IgE of patients in the included studies

From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review

Study ID Interventions Age (mean ± SD) Female sex n(%) Caucasian n(%) Weight (kg) mean ± SD <80 kg n (%) IgE (IU/mL) mean ± SD IgE (IU/mL) median (range)
1 Omalizumab 75-375 39.1 ± 9.0 19 (70.4) 27 (100.0) 81.9 ± 20.2 - 211 ± 158 -
Placebo 42.3 ± 15.0 19 (86.4) 22 (100.0) 71.2 ± 12.4 - 181 ± 136 -
2 Omalizumab 75 38.8 ± 15.5 15 (65.2) 20 (87.0) 80.5 ± 21.6 14 (60.9) 251.5 ± 389.6 62 (3–1500)
Omalizumab 300 42.9 ± 15.7 17 (68.0) 19 (76.0) 82.2 ± 22.8 13 (52.0) 170.5 ± 178.5 131.5 (2–819)
Omalizumab 600 40 ± 11.1 12 (57.1) 18 (85.7) 80.6 ± 18.1 11 (52.4) 134.9 ± 142.9 90 (4–617)
Placebo 41.2 ± 16.2 17 (81) 18 (85.7) 80.4 ± 24.8 13 (61.9) 297.4 ± 748.9 62 (3–1500)
3 Omalizumab 75 39.7 ± 15.0 61 (74.0) 64 (78.0) 82.8 ± 21.2 43 (52.4) 168.2 ± 321.9** 79
Omalizumab 150 43.0 ± 13.2 65 (79.0) 70 (85.0) 82.4 ± 20.7 41 (49.4) - -
Omalizumab 300 44.3 ± 13.7 63 (80.0) 68 (86.0) 80.3 ± 19.9 41 (51.9) - -
Placebo 43.1 ± 12.5 55 (70.0) 70 (89. 0) 84.3 ± 25.7 41 (51.9) - -
4 Omalizumab 300 42.7 ± 17.9 186 (73.8) 223 (88.5) 29.4 ± 7.1* - 162.3 ± 306.4 79 (1–3050)
Placebo 44.3 ± 14.7 55 (66.3) 75 (90.4) 31 ± 9.6* - 147.2 ± 224.4 71 (1–1230)
5 Omalizumab 75 40.7 ± 15.2 55 (71.4) 62 (80.5) 81.1 ± 19.2 38 (48.7) - 91 (1–2030)
Omalizumab 150 41.1 ± 14 64 (80.0) 63 (78.8) 83.2 ± 24.4 40 (50.0) - 71 (1–5000)
Omalizumab 300 42.4 ± 13.2 60 (74.1) 74 (91.4) 81.6 ± 19.7 45 (55.5) - 85.5 (1–2330)
Placebo 40.4 ± 15.6 52 (65.0) 64 (80.0) 83 ± 20.5 35 (43.7) - 92 (1–1010)
  1. *BMI (kg/m2). **mean and SD of all patients included. SD: standard deviation. IgE: Immunoglobulin E normal range 13 to 127 IU/mL.